FDG PET imaging for grading and prediction of outcome in chondrosarcoma patients

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 31, Issue 2, 2004, Pages 189-195

  Brenner, Winfried ^a   Conrad, Ernest U ^a   Eary, Janet F ^a  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

Chondrosarcoma; Fluorodeoxyglucose; Positron emission tomography; Standardized uptake value

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER SIZE; CHONDROSARCOMA; CLINICAL ARTICLE; CORRELATION ANALYSIS; DISEASE COURSE; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; MALE; METASTASIS; POSITRON EMISSION TOMOGRAPHY; RELAPSE; SENSITIVITY AND SPECIFICITY; STANDARDIZATION;

ADULT; AGED; AGED, 80 AND OVER; BONE NEOPLASMS; CHONDROSARCOMA; DISEASE-FREE SURVIVAL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TOMOGRAPHY, EMISSION-COMPUTED; WASHINGTON;

EID: 0842333881     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-003-1353-4     Document Type: Article

References (20)

1. Evans HL, Ayala AG, Romsdahl MM. Prognostic factors in chondrosarcoma of bone: a clinicopathologic analysis with emphasis on histologic grading. Cancer 1977; 40:818-831.
2. Arsos G, Venizelos I, Karatzas N, Koukoulidis A, Karakatsanis C. Low-grade chondrosarcomas: a difficult target for radionuclide imaging. Case report and review of the literature. Eur J Radiol 2002; 43:66-72.
3. Aoki J, Watanabe H, Shinozaki T, et al. FDG PET of primary benign and malignant bone tumors: standardized uptake value in 52 lesions. Radiology 2001; 219:774-777.
4. Eary JF, O'Sullivan F, Powitan Y, et al. Sarcoma tumor FDG uptake measured by PET and patient outcome: a retrospective analysis. Eur J Nucl Med 2002; 29:1149-1154.
5. Eary JF, Conrad EU, Bruckner JD, et al. Quantitative [F-18]fluorodeoxyglucose positron emission tomography in pretreatment and grading of sarcoma. Clin Cancer Res 1998; 4:1215-1220.
6. Folpe AL, Lyles RH, Sprouse JT, Conrad EU, Eary JF. (F-18) fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma. Clin Cancer Res 2000; 6:1279-1287.
7. Garcia R, Kim EE, Wong FC, et al. Comparison of fluorine-18-FDG PET and technetium-99m-MIBI SPECT in evaluation of musculoskeletal sarcomas. J Nucl Med 1996; 37:1476-1479.
8. Schulte M, Brecht-Krauss D, Heymer B, et al. Grading of tumors and tumorlike lesions of bone: evaluation by FDG PET. J Nucl Med 2000; 41:1695-1701.
9. Watanabe H, Shinozaki T, Yanagawa T, et al. Glucose metabolic analysis of musculoskeletal tumours using 18fluorine-FDG PET as an aid to preoperative planning. J Bone Joint Surg Br 2000; 82:760-767.
10. Aoki J, Watanabe H, Shinozaki T, et al. FDG-PET in differential diagnosis and grading of chondrosarcomas. J Comput Assist Tomogr 1999; 23:603-608.
11. DeGrado TR, Turkington TG, Williams JJ, et al. Performance characteristics of a whole-body PET scanner. J Nucl Med 1994; 35:1398-1406.
12. Lewellen TK, Kohlmeyer S, Miyaoka R, Schubert S, Stearns C. Investigation of the count rate performance of the General Electric Advance positron emission tomograph. IEEE Trans Nucl Sci 1995; 42:1051-1057.
13. Bovee JVMG, Hogendoorn PCW. Cartilage-forming tumours of bone and soft tissue and their differential diagnosis. Curr Diagn Pathol 2001; 7:223-234.
14. Meis-Kindblom JM, Bergh P, Gunterberg B, Kindblom LG. Extraskeletal myxoid chondrosarcoma: a reappraisal of its morphologic spectrum and prognostic factors based on 117 cases. Am J Surg Pathol 1999; 26:636-650.
15. Rubin BP, Fletcher JA. Skeletal and extraskeletal myxoid chondrosarcoma: related or distinct tumors? Adv Anat Pathol 1999; 6:204-212.
16. Fiorenza F, Abudu A, Grimer RJ, et al. Risk factors for survival and local control in chondrosarcoma of bone. J Bone Joint Surg Br 2002; 84:93-99.
17. Allal AS, Dulguerov P, Allaoua M, et al. Standardized uptake value of 2-[(18)F] fluoro-2-deoxy-D-glucose in predicting outcome in head and neck carcinomas treated by radiotherapy with or without chemotherapy. J Clin Oncol 2002; 20:1398-1404.
18. Graham MM, Peterson LM, Hayward RM. Comparison of simplified quantitative analyses of FDG uptake. Nucl Med Biol 2000; 27:647-655.
19. Higashi K, Ueda Y, Ayabe K, et al. FDG PET in the evaluation of the aggressiveness of pulmonary adenocarcinoma: correlation with histopathological features. Nucl Med Commun 2000; 21:707-714.
20. Dhital K, Saunders CA, Seed PT, O'Doherty MJ, Dussek J. [(18)F]Fluorodeoxyglucose positron emission tomography and its prognostic value in lung cancer. Eur J Cardiothorac Surg 2000; 18:425-428.